10x Genomics (TXG) Cost of Revenue (2018 - 2026)

10x Genomics has disclosed Cost of Revenue across 9 years of filings, most recently posting $38.5 million for Q2 2026.

• In Q2 2026, Cost of Revenue fell 19.41% year-over-year to $38.5 million; the TTM figure through Jun 2026 stood at $184.9 million (down 5.95% YoY), while the FY2025 annual figure was $198.9 million, up 1.34% from the prior year.
• Cost of Revenue came in at $38.5 million for Q2 2026 at 10x Genomics, down from $44.7 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $68.2 million in Q4 2023 to a low of $25.5 million in Q1 2022.
• Average Cost of Revenue over 5 years is $44.9 million, with a median of $47.5 million recorded in 2023.
• Year-over-year, Cost of Revenue jumped 463.66% in 2022 and decreased 22.12% in 2024.
• Over 5 years, Cost of Revenue stood at $36.8 million in 2022, then soared by 85.18% to $68.2 million in 2023, then slipped by 20.72% to $54.1 million in 2024, then retreated by 2.0% to $53.0 million in 2025, then fell by 27.26% to $38.5 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $38.5 million in Q2 2026, $44.7 million in Q1 2026, and $53.0 million in Q4 2025.